Pharmacokinetic and pharmacodynamic properties of meropenem (Q37247125)

19 August 2017

1 reference

title

Pharmacokinetic and pharmacodynamic properties of meropenem (English)

1 reference

19 August 2017

1 reference

1 reference

David P Nicolau

1

1 reference

PubMed ID

18713048

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Clinical Infectious Diseases

19 August 2017

1 reference

19 August 2017

47 Suppl 1

1 reference

19 August 2017

S32-40

1 reference

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

19 August 2017

1 reference

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

21 January 2018

1 reference

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice

21 January 2018

1 reference

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

A compilation of meropenem tissue distribution data

21 January 2018

1 reference

Pharmacokinetics of meropenem in patients with intra-abdominal infections

21 January 2018

1 reference

Tissue penetration of Meropenem in patients undergoing gynecologic surgery

21 January 2018

1 reference

Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem

21 January 2018

1 reference

Meropenem pharmacokinetics and penetration into an inflammatory exudate

21 January 2018

1 reference

Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister Fluid

21 January 2018

1 reference

Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment

21 January 2018

1 reference

Pharmacokinetics of meropenem in subjects with renal insufficiency

21 January 2018

1 reference

Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

21 January 2018

1 reference

Pharmacokinetics of meropenem in subjects with various degrees of renal impairment

21 January 2018

1 reference

Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration

21 January 2018

1 reference

Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment

21 January 2018

1 reference

Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men

21 January 2018

1 reference

Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children

21 January 2018

1 reference

The pharmacokinetics of meropenem in infants and children: a population analysis

21 January 2018

1 reference

Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients

21 January 2018

1 reference

Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem

21 January 2018

1 reference

Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model

21 January 2018

1 reference

Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model

21 January 2018

1 reference

Making the most of surveillance studies: summary of the OPTAMA Program

21 January 2018

1 reference

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

21 January 2018

1 reference

The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe

21 January 2018

1 reference

Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.

21 January 2018

1 reference

Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program

21 January 2018

1 reference

Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program

21 January 2018

1 reference

Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program

21 January 2018

1 reference

Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program

21 January 2018

1 reference

Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia

21 January 2018

1 reference

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

21 January 2018

1 reference

Use of Monte Carlo Simulation to Design an Optimized Pharmacodynamic Dosing Strategy for Meropenem

21 January 2018

1 reference

Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation

21 January 2018

1 reference

Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

21 January 2018

1 reference

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

21 January 2018

1 reference

Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.

21 January 2018

1 reference

Continuous infusion versus intermittent administration of meropenem in critically ill patients

21 January 2018

1 reference

Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.

21 January 2018

1 reference

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance

21 January 2018

1 reference

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/590064

1 reference

19 August 2017

1 reference

PubMed ID

18713048